Bioarray of Elche, Spain, has launched a preimplantation genetic screening service of embryos using next-generation sequencing. According to the company, using NGS for PGS is less expensive than older techniques and can be combined with preimplantation genetic diagnosis.
Omicia is integrating its Phevor Phenotype Driven Variant Ontological Re-ranking tool into its Opal platform, including the recently launched Opal Clinical genomic interpretation platform. Phevor, which the company developed with the University of Utah, speeds up the identification of disease-relevant variants in genomic sequences. It allows clinicians to integrate patient symptoms and information about their condition to prioritize genetic variants.
Vela Diagnostics of Singapore has launched the Sentosa SQ Non-Small Cell Lung Cancer Panel and the Sentosa Colorectal Cancer Panel for early access customers. Both panels, which are for research use only, are part of Vela's series of NGS oncology panels. They target 11 genes with 28 amplicons and have a turnaround time of two days. The Sentosa NSCLC panel screens for 113 mutations and the Sentosa SQ CRC panel for 112 mutations.